DD146186A5 - Verfahren zur herstellung einer 4a,9b-hexahydro-ypsilon-verbindung - Google Patents

Verfahren zur herstellung einer 4a,9b-hexahydro-ypsilon-verbindung Download PDF

Info

Publication number: DD146186A5
Authority: DD; German Democratic Republic
Prior art keywords: trans; hexahydro; formula; compound; compounds
Prior art date: 1977-05-23

Application number

DD215016A

Other languages

German (de)

English (en)

Inventor

Welch, Jr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-05-23

Filing date

1978-05-19

Publication date

1981-01-28

1978-05-19 Application filed by Pfizer filed Critical Pfizer

1981-01-28 Publication of DD146186A5 publication Critical patent/DD146186A5/de

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 40
238000004519 manufacturing process Methods 0.000 title 1
-1 lithium aluminum hydride Chemical compound 0.000 claims abstract description 22
239000002253 acid Substances 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
229910052731 fluorine Inorganic materials 0.000 claims abstract description 11
239000012458 free base Substances 0.000 claims abstract description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 7
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
239000011737 fluorine Substances 0.000 claims abstract description 6
238000002360 preparation method Methods 0.000 claims abstract description 6
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract description 5
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
239000012280 lithium aluminium hydride Substances 0.000 claims abstract description 3
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims abstract 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract 2
239000012442 inert solvent Substances 0.000 claims abstract 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 7
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 6
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
239000012467 final product Substances 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 description 12
239000000203 mixture Substances 0.000 description 11
230000002936 tranquilizing effect Effects 0.000 description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
239000003204 tranquilizing agent Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 8
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
239000002585 base Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
229940025084 amphetamine Drugs 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
239000003814 drug Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
QAVHEZZLPMXZCG-UHFFFAOYSA-N 4-oxo-4-phenylbut-2-ynoic acid Chemical compound OC(=O)C#CC(=O)C1=CC=CC=C1 QAVHEZZLPMXZCG-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
230000006399 behavior Effects 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
150000002475 indoles Chemical class 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000000698 schizophrenic effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229940125725 tranquilizer Drugs 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
MEUAAEMCZUPORO-LRSHZYOCSA-N (9z)-n,n-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide;dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl.C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 MEUAAEMCZUPORO-LRSHZYOCSA-N 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical class OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 1
SHKWSBAVRQZYLE-UHFFFAOYSA-N 5-oxo-5-phenylpentanoic acid Chemical class OC(=O)CCCC(=O)C1=CC=CC=C1 SHKWSBAVRQZYLE-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
206010014557 Emotional poverty Diseases 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940054051 antipsychotic indole derivative Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000008038 benzoazepines Chemical class 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 1
DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
QRNDDJXJUHBGSG-UHFFFAOYSA-N methoxyethyne Chemical group COC#C QRNDDJXJUHBGSG-UHFFFAOYSA-N 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
IXRNQIKIVWWFBH-UHFFFAOYSA-N n-(1-phenylethenyl)acetamide Chemical compound CC(=O)NC(=C)C1=CC=CC=C1 IXRNQIKIVWWFBH-UHFFFAOYSA-N 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000004044 response Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000004449 solid propellant Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD215016A 1977-05-23 1978-05-19 Verfahren zur herstellung einer 4a,9b-hexahydro-ypsilon-verbindung DD146186A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US79939277A	1977-05-23	1977-05-23

Publications (1)

Publication Number	Publication Date
DD146186A5 true DD146186A5 (de)	1981-01-28

Family

ID=25175793

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DD215016A DD146186A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung einer 4a,9b-hexahydro-ypsilon-verbindung
DD78215015A DD145536A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung von trans-2-substituierten-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido(4,3-b)-indolderivaten
DD78215017A DD145537A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung einer 4a,9b-transhexahydro-gamma-carbolin-verbindung
DD78205479A DD138321A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung von trans-2-substituierten-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu-indolinderivaten

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DD78215015A DD145536A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung von trans-2-substituierten-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido(4,3-b)-indolderivaten
DD78215017A DD145537A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung einer 4a,9b-transhexahydro-gamma-carbolin-verbindung
DD78205479A DD138321A5 (de)	1977-05-23	1978-05-19	Verfahren zur herstellung von trans-2-substituierten-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu-indolinderivaten

Country Status (31)

Country	Link
JP (1)	JPS53144600A (cs)
AR (2)	AR217688A1 (cs)
AT (1)	AT368995B (cs)
AU (1)	AU499618B1 (cs)
BE (1)	BE867249A (cs)
CA (1)	CA1094071A (cs)
CH (1)	CH634321A5 (cs)
CS (1)	CS207612B2 (cs)
DD (4)	DD146186A5 (cs)
DE (1)	DE2822465C2 (cs)
DK (1)	DK226678A (cs)
EG (1)	EG13590A (cs)
FI (1)	FI63402C (cs)
FR (1)	FR2392023A1 (cs)
GB (1)	GB1586655A (cs)
GR (1)	GR69985B (cs)
HU (3)	HU187782B (cs)
IE (1)	IE46975B1 (cs)
IL (1)	IL54755A (cs)
IT (1)	IT1096307B (cs)
LU (1)	LU79684A1 (cs)
NL (1)	NL7804210A (cs)
NO (2)	NO150204C (cs)
NZ (1)	NZ187333A (cs)
PH (1)	PH13756A (cs)
PL (5)	PL117107B1 (cs)
PT (1)	PT68058B (cs)
SE (2)	SE441448B (cs)
SU (4)	SU873883A3 (cs)
YU (4)	YU91478A (cs)
ZA (1)	ZA782918B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4224329A (en) *	1979-01-23	1980-09-23	Pfizer Inc.	2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles
US4451655A (en) *	1982-05-17	1984-05-29	Pfizer Inc.	Process for preparing carboline derivatives and compounds used in their preparation
RU2106864C1 (ru) *	1995-10-23	1998-03-20	Николай Серафимович Зефиров	Средство для лечения болезни альцгеймера
US6974825B1 (en)	1996-12-20	2005-12-13	Astrazeneca Canada Inc.	Compounds with analgesic effect
SE9604786D0 (sv)	1996-12-20	1996-12-20	Astra Pharma Inc	New compounds
SE9904675D0 (sv)	1999-12-20	1999-12-20	Astra Pharma Inc	Novel compounds
SE0101769D0 (sv)	2001-05-18	2001-05-18	Astrazeneca Ab	Novel compounds
SE0101771D0 (sv)	2001-05-18	2001-05-18	Astrazeneca Ab	Novel compounds
SE0101770D0 (sv)	2001-05-18	2001-05-18	Astrazeneca Ab	Novel compounds
SE0101773D0 (sv)	2001-05-18	2001-05-18	Astrazeneca Ab	Novel compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR205452A1 (es) *	1973-12-06	1976-05-07	Endo Lab	Metodo para preparar nuevos trans-2, 3, 4, 4a, 5, 9b-hexahidro-5-fenil-1h-pirido(4,3-b) indoles
JPS50126699A (cs) *	1974-03-20	1975-10-04
US4001263A (en) *	1974-04-01	1977-01-04	Pfizer Inc.	5-Aryl-1,2,3,4-tetrahydro-γ-carbolines

1978
- 1978-03-30 SE SE7803625A patent/SE441448B/sv unknown
- 1978-04-17 PH PH21013A patent/PH13756A/en unknown
- 1978-04-18 YU YU00914/78A patent/YU91478A/xx unknown
- 1978-04-20 NL NL7804210A patent/NL7804210A/xx not_active Application Discontinuation
- 1978-04-24 AU AU35377/78A patent/AU499618B1/en not_active Expired
- 1978-04-25 EG EG276/78A patent/EG13590A/xx active
- 1978-04-28 AR AR271956A patent/AR217688A1/es active
- 1978-05-18 SU SU782615898A patent/SU873883A3/ru active
- 1978-05-18 HU HU822639A patent/HU187782B/hu unknown
- 1978-05-18 PL PL1978215921A patent/PL117107B1/pl unknown
- 1978-05-18 PL PL1978215923A patent/PL116944B1/pl unknown
- 1978-05-18 HU HU78PI626A patent/HU185009B/hu unknown
- 1978-05-18 GB GB20350/78A patent/GB1586655A/en not_active Expired
- 1978-05-18 HU HU822638A patent/HU188802B/hu unknown
- 1978-05-18 CS CS783239A patent/CS207612B2/cs unknown
- 1978-05-18 PL PL1978215922A patent/PL114541B1/pl unknown
- 1978-05-18 PL PL1978206903A patent/PL114547B1/pl unknown
- 1978-05-19 DD DD215016A patent/DD146186A5/de unknown
- 1978-05-19 DD DD78215015A patent/DD145536A5/de unknown
- 1978-05-19 DD DD78215017A patent/DD145537A5/de unknown
- 1978-05-19 DD DD78205479A patent/DD138321A5/xx unknown
- 1978-05-19 BE BE187842A patent/BE867249A/xx not_active IP Right Cessation
- 1978-05-19 PT PT68058A patent/PT68058B/pt unknown
- 1978-05-19 CA CA303,710A patent/CA1094071A/en not_active Expired
- 1978-05-20 GR GR56281A patent/GR69985B/el unknown
- 1978-05-22 DK DK226678A patent/DK226678A/da not_active Application Discontinuation
- 1978-05-22 FI FI781612A patent/FI63402C/fi not_active IP Right Cessation
- 1978-05-22 IL IL54755A patent/IL54755A/xx unknown
- 1978-05-22 JP JP6087278A patent/JPS53144600A/ja active Granted
- 1978-05-22 IE IE1013/78A patent/IE46975B1/en unknown
- 1978-05-22 NZ NZ187333A patent/NZ187333A/en unknown
- 1978-05-22 AT AT0369678A patent/AT368995B/de not_active IP Right Cessation
- 1978-05-22 IT IT23673/78A patent/IT1096307B/it active
- 1978-05-22 LU LU79684A patent/LU79684A1/xx unknown
- 1978-05-22 ZA ZA00782918A patent/ZA782918B/xx unknown
- 1978-05-22 CH CH552678A patent/CH634321A5/fr not_active IP Right Cessation
- 1978-05-22 FR FR7815029A patent/FR2392023A1/fr active Granted
- 1978-05-22 NO NO781770A patent/NO150204C/no unknown
- 1978-05-23 DE DE2822465A patent/DE2822465C2/de not_active Expired
1979
- 1979-04-16 AR AR276191A patent/AR221721A1/es active
- 1979-04-24 SU SU792753359A patent/SU843749A3/ru active
- 1979-04-26 SU SU792759902A patent/SU818484A3/ru active
- 1979-05-18 PL PL20690379A patent/PL206903A1/xx unknown
- 1979-05-18 SU SU792763595A patent/SU841589A3/ru active
1982
- 1982-10-01 YU YU02218/82A patent/YU221882A/xx unknown
- 1982-10-01 YU YU02216/82A patent/YU221682A/xx unknown
- 1982-10-01 YU YU2217/82A patent/YU40796B/xx unknown
1983
- 1983-05-20 NO NO831790A patent/NO151862C/no unknown
- 1983-10-27 SE SE8305917A patent/SE448459B/sv not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO151862B (no)	1985-03-11
FR2392023A1 (fr)	1978-12-22
FI63402C (fi)	1983-06-10
AR217688A1 (es)	1980-04-15
YU221782A (en)	1983-01-21
FR2392023B1 (cs)	1980-11-07
PL117107B1 (en)	1981-07-31
DD145536A5 (de)	1980-12-17
YU221882A (en)	1983-01-21
HU185009B (en)	1984-11-28
IL54755A (en)	1981-02-27
AR221721A1 (es)	1981-03-13
CS207612B2 (en)	1981-08-31
SU818484A3 (ru)	1981-03-30
PL114547B1 (en)	1981-02-28
YU221682A (en)	1983-01-21
PL116944B1 (en)	1981-07-31
NL7804210A (nl)	1978-11-27
SE8305917L (sv)	1983-10-27
PT68058B (en)	1979-10-24
SU841589A3 (ru)	1981-06-23
JPS5711912B2 (cs)	1982-03-08
IT1096307B (it)	1985-08-26
BE867249A (fr)	1978-11-20
PL206903A1 (pl)	1979-10-22
SE7803625L (sv)	1978-11-24
CH634321A5 (en)	1983-01-31
YU40796B (en)	1986-06-30
AU499618B1 (en)	1979-04-26
IT7823673A0 (it)	1978-05-22
NO151862C (no)	1985-06-19
IL54755A0 (en)	1978-07-31
PT68058A (en)	1978-06-01
LU79684A1 (fr)	1979-12-06
HU187782B (en)	1986-02-28
SU873883A3 (ru)	1981-10-15
DE2822465C2 (de)	1986-08-28
YU91478A (en)	1983-01-21
SE8305917D0 (sv)	1983-10-27
PL114541B1 (en)	1981-02-28
SU843749A3 (ru)	1981-06-30
IE46975B1 (en)	1983-11-16
FI63402B (fi)	1983-02-28
IE781013L (en)	1978-11-23
ATA369678A (de)	1982-04-15
NO150204C (no)	1984-09-05
GR69985B (cs)	1982-07-22
NO150204B (no)	1984-05-28
HU188802B (en)	1986-05-28
ZA782918B (en)	1979-06-27
EG13590A (en)	1982-03-31
GB1586655A (en)	1981-03-25
NO831790L (no)	1978-11-24
AT368995B (de)	1982-11-25
CA1094071A (en)	1981-01-20
DD145537A5 (de)	1980-12-17
SE441448B (sv)	1985-10-07
DK226678A (da)	1978-11-24
SE448459B (sv)	1987-02-23
JPS53144600A (en)	1978-12-15
DE2822465A1 (de)	1978-11-30
NO781770L (no)	1978-11-24
NZ187333A (en)	1984-05-31
DD138321A5 (de)	1979-10-24
FI781612A7 (fi)	1978-11-24
PH13756A (en)	1980-09-17

Publication	Publication Date	Title
DE2657013C2 (de)	1985-11-14	1-(3-Dimethylaminopropyl)-phthalane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2760372C2 (cs)	1991-05-29
EP0136658B1 (de)	1989-04-26	1-Benzyl-aminoalkyl-pyrrolidinone und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel
WO1985002847A1 (fr)	1985-07-04	Esters et amides d'acides carboniques carbocycliques et heterocycliques d'amines ou d'alcools azotes cycliques portes et non portes
DE2820938A1 (de)	1978-11-23	Neue imidazoazine und imidazodiazine
DE3002367A1 (de)	1980-07-24	2-substituierte trans-5-aryl-2,3,4,4a,5, 9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
DD146186A5 (de)	1981-01-28	Verfahren zur herstellung einer 4a,9b-hexahydro-ypsilon-verbindung
EP0189370A2 (de)	1986-07-30	Spiro-dioxolane, -dithiolane und -oxothiolane
EP0024560B1 (de)	1983-04-13	Neue 3-Amino-1-benzoxepin-Derivate und ihre Salze; Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2817661A1 (de)	1978-11-02	Neue isoindolinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
DE68905363T2 (de)	1993-08-05	Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
DE2425767A1 (de)	1975-01-09	3-alkyl-9-aminoalkyl-1,2,3,4-tetrahydrocarbazole und ihre verwendung in arzneimitteln
CH556837A (de)	1974-12-13	Verfahren zur herstellung neuer spiroindanpyrrolidinderivate.
CH635342A5 (de)	1983-03-31	Verfahren zur herstellung von neuen octahydro-indolo(2,3-a)-chinolizinen.
EP0180833B1 (de)	1989-07-19	4-Oxo-pyrido[2,3]pyrimidin-Derivate, Verfahren zur deren Herstellung und diese ethaltende Arzneimittel
CH654833A5 (de)	1986-03-14	4-aryl-2-methyl-1,2,3,4-tetrahydro-isochinolin-derivate.
AT375079B (de)	1984-06-25	Verfahren zur herstellung von neuen trans-2,3,4,4a ,5,9b-hexahydro-1h-pyrido(4,3-b)indolen und ihren pharmazeutisch annehmbaren salzen
AT395852B (de)	1993-03-25	Imidazolyl-methyl-tetrahydrothiophenderivate
DE2514084A1 (de)	1975-11-20	Neue indolverbindungen
DE3103080A1 (de)	1981-12-17	"spiro (dihydrobenzofuran-piperidine und -pyrrolidine)"
DE2550163A1 (de)	1976-05-20	Neue derivate des eckige klammer auf 1,4 eckige klammer zu oxathiino eckige klammer auf 2,3-c eckige klammer zu pyrrols, deren herstellung und diese enthaltende zusammensetzungen
EP0056616B1 (de)	1985-08-21	Cycloheptenderivate, Verfahren zu ihrer Herstellung, sowie diese enthaltende Arzneimittel
DE2221808A1 (de)	1972-11-16	Verfahren zur Herstellung neuer heterocyclischer Verbindungen
EP0014996B1 (de)	1982-04-28	Heterocyclische spiroverknüpfte Amidine, ihre Stereoisomeren und optischen Isomeren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2606789A1 (de)	1976-09-02	Oxoindanylpropionsaeuren und verfahren zu ihrer herstellung